Challenges with coverage with evidence development schemes for medical devices: A systematic review by Reckers-Droog, V.T. (Vivian) et al.
ARTICLE IN PRESS 
JID: HLPT [m5G; February 29, 2020;8:31 ] 
Health Policy and Technology xxx (xxxx) xxx 
Contents lists available at ScienceDirect 
Health Policy and Technology 
journal homepage: www.elsevier.com/locate/hlpt 
Challenges with coverage with evidence development schemes for 
medical devices: A systematic review 
Vivian Reckers-Droog a , ∗, Carlo Federici b , c , Werner Brouwer a , d , Michael Drummond e 
a Erasmus School of Health Policy & Management, Erasmus University Rotterdam, P.O. Box 1738, Rotterdam 30 0 0 DR, the Netherlands 
b Centre for Research on Health and Social Care Management, Bocconi University, Italy 
c School of Engineering, Warwick University, United Kingdom 
d Erasmus School of Economics, Erasmus University Rotterdam, the Netherlands 
e Centre for Health Economics, University of York, United Kingdom 
a r t i c l e i n f o 
Article history: 
Available online xxx 
Keywords: 
Coverage with evidence development 
Performance based risk sharing agreements 
Health technology assessment 
Decision uncertainty 
Medical devices 
a b s t r a c t 
Objectives: Coverage with evidence development (CED) schemes are particularly relevant for medical 
devices (MDs), since clinical evidence is often limited at the time of launch and their long-term (cost- 
) effectiveness heavily depends on how they are adopted into routine clinical practice. The objective of 
this study was to identify and describe the challenges that payers and manufacturers might face when 
assessing the desirability of, choosing the research design for, implementing, and evaluating CED schemes 
for MDs. 
Methods: A systematic literature review was performed on six databases following PRISMA guidelines. 
Two independent reviewers assessed the eligibility of studies based on predeﬁned criteria and extracted 
data from the included articles by using a pre-deﬁned extraction template. The data were synthesised in 
a narrative review. 
Results: The systematic search yielded 4293 articles of which 27 were eligible for inclusion. We identiﬁed 
20 challenges that are associated with CED schemes for MDs. Five of these challenges relate directly to 
the characteristics of MDs, and hence are speciﬁc to MDs. These challenges concern deciding on whether 
a CED scheme is required, understanding the relevant uncertainties and risks, identifying meaningful out- 
comes, deﬁning an adequate duration for a scheme, and market entry of new technologies. 
Conclusions: Payers and manufacturers of MDs have to address the identiﬁed challenges to improve a 
CED scheme’s chance of success. This can be further improved by public sharing of information about 
the outcome of applied schemes and way in which stakeholders have addressed the challenges they faced 
when applying a CED scheme. 
© 2020 Fellowship of Postgraduate Medicine. Published by Elsevier Ltd. 
This is an open access article under the CC BY-NC-ND license. 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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Decisions about the coverage and reimbursement of new health
echnologies are inherently uncertain as, at the time of market
aunch, only limited information is available about their real-world
erformance [1] . Uncertainties typically concern: (1) the safety and
relative) clinical effectiveness of a technology in a speciﬁed pa-
ient population, measured by short- and long-term outcomes that∗ Corresponding author. 
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schemes for medical devices: A systematic review, Health Policy and Tre relevant for patients, (2) the value for money of a technology
nd the question whether its reimbursement is considered an eﬃ-
ient use of available resources, (3) the adoption and diffusion of a
echnology, such as the rate of uptake, disease areas in which the
echnology may be used, possible off-label use, and number of pa-
ients who may beneﬁt from the technology, and, related to this,
4) the budget impact following adoption, i.e. the ﬁnancial impact
n the healthcare system, including additional costs and cost sav-
ngs associated with reimbursing the technology [e.g. 1–4 ]. 
These uncertainties may be considerable, especially when
overage and reimbursement decisions are taken close to the
ime of product approval (e.g. licensing or Conformité Européennean open access article under the CC BY-NC-ND license. 
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Wmarking) and when they are inextricably linked to the character-
istics of the technology, as is often the case for medical devices
(MDs) [1] . For example, MDs frequently undergo product modi-
ﬁcations that may affect their eﬃcacy and costs, they often have
multiple applications, and their eﬃcacy may not only depend on
characteristics of the MD itself but also on the skills and experi-
ence of those applying a MD in clinical practice [5] . Furthermore,
uncertainties associated with safety, eﬃcacy, and (cost-) effective-
ness may be particularly relevant for MDs, as requirements for
product approval are often less clear and the level of evidence sup-
porting regulatory and market approval are typically less stringent
than for pharmaceuticals [5–7] . Although market approval regu-
lations for MDs will become more stringent in Europe from May
2020 onwards, the uncertainties associated with coverage and re-
imbursement of MDs will likely continue to exist as the most strin-
gent rules will only apply to a small number of MDs, i.e. class III
(high-risk) MDs, including implants [7 , 8] , and even these rules do
not eliminate the full range and extent of uncertainty highlighted
above. 
Traditionally, payers have borne the ﬁnancial risk of making
‘wrong’ coverage and reimbursement decisions in the presence of
uncertainties regarding the real-world performance of health tech-
nologies. A wrong decision may occur when a health technology
is reimbursed for which later its original claims on safety, eﬃ-
cacy, and/or (cost-) effectiveness are not conﬁrmed (type I error)
or when a technology is not reimbursed but later is shown to be
more safe and (cost-) effective than relevant comparators used in
clinical practice (type II error) [6 , 9 , 10] . Regardless of the type of
error, any wrong decision is undesirable as it will likely always
lead to loss of beneﬁts to patients (directly or indirectly) and an
ineﬃcient use of available resources. The risk of making a wrong
decision and the evidence gap between requirements for regula-
tory and market approval on the one hand and coverage and re-
imbursement decisions on the other hand have led to the intro-
duction and increased use of ‘coverage with evidence development
(CED)’ schemes [e.g. 2 , 4 , 10 ]. 
CED schemes aim to reduce uncertainties associated with the
safety, eﬃcacy, and (cost-) effectiveness of health technologies.
They allow temporary reimbursement of the MD, while more data
are being collected to enable making a better informed deci-
sion at a later stage, while sharing the risk of a wrong positive
(temporary) coverage or reimbursement decision between payers
and manufacturers during a CED scheme [e.g. 1 , 3 , 6 ]. Thus, they
avoid uncertain and potentially wrong negative decisions and al-
low more informed decisions without delaying access to the MD
for patients. These schemes go under different names in differ-
ent countries, for example, ‘coverage with evidence development
schemes’ in the USA, ‘conditionally funded ﬁeld evaluations’ in
Canada (Ontario), ‘interim funding schemes’ in Australia, ‘only in
research (OIR)’ and ‘only with research (OWR)’ in the UK (Eng-
land/Wales), and ‘conditional reimbursement schemes’ in Belgium
and the Netherlands [12 , 14] . However, these schemes can all be
labelled as performance-based risk sharing agreements (PBRSAs),
i.e. “a plan by which the [clinical] performance of the product is
tracked in a deﬁned patient population over a speciﬁed period of
time and the level or continuation of reimbursement is based on
the health and economic outcomes achieved” [1] . Following this
deﬁnition, CED schemes cover schemes that manage utilization in
the real world and link reimbursement to the performance of a
health technology as well as schemes that provide additional evi-
dence with the aim to reduce decision uncertainty [1] . 
Despite the growing interest in CED schemes, they are often
costly, complex, and challenging [2 , 15] . In response to these chal-
lenges, ISPOR’s ‘Good Practices for PBRSA Task Force’ formulated
four good practice questions that need to be addressed when con-
sidering the use of a CED scheme. These questions concern: (1) thePlease cite this article as: V. Reckers-Droog, C. Federici and W. Brouw
schemes for medical devices: A systematic review, Health Policy and Tesirability of the scheme (as opposed to some other reimburse-
ent or research arrangement), (2) the choice of research design,
3) the approach to implementation, and 4) the method used for
valuating the scheme [1] . In principle, the use of CED schemes
eems particularly relevant to MDs, since clinical evidence is often
imited at the time of launch and the long-term effectiveness and
ost-effectiveness is heavily dependent on how they are adopted
nto routine clinical practice. Therefore, the objective of this study
as to identify and describe the challenges that payers and man-
facturers might face in light of the four good practice questions
hen applying CED schemes for MDs. The results should be of in-
erest to those who (consider to) apply or design CED schemes for
Ds and want to improve a scheme’s chance of success. 
ethods 
The systematic review was conducted following the Preferred
eported Items for Systematic Review and Meta-Analysis (PRISMA)
ramework [16] . The PRISMA checklist is available as Supplemen-
ary Material S1. 
ligibility criteria 
We included studies in the review if they met the follow-
ng eligibility criteria: (1) the article is a primary study, meta-
nalysis/review, letter, editorial, or note, (2) the article discusses
in-depth) the challenges associated with CED schemes for MDs,
3) the article is written in English, Italian, Spanish, Portuguese, or
utch, (4) the article is published between 20 0 0 and 2019, and (5)
he full text is available. 
Following the European Union Directive 2007/47/EC, we deﬁned
Ds as “any instrument, apparatus, appliance, software, material
r other article, whether used alone or in combination, together
ith any accessories, including the software intended by its man-
facturer to be used speciﬁcally for diagnostic, and/or therapeu-
ic purposes and necessary for its proper application, intended by
he manufacturer to be used for human beings for the purpose of
iagnosis, prevention, treatment, monitoring or alleviation of dis-
ase”. For our main analysis, we included studies that discussed
hallenges with CED schemes (i) in the speciﬁc context of MDs
nd (ii) the context of different types of health technologies if this
ncluded MDs. To enable a secondary analysis, in which we com-
ared challenges associated with CED schemes for MDs with those
or pharmaceuticals, we also included studies that discussed chal-
enges with CED schemes solely in the context of pharmaceuticals.
e excluded studies that merely reported on the characteristics,
rocesses, and/or results of applied CED schemes for MDs and that
iscussed challenges solely in the context of ﬁnancial agreements
etween payer and manufacturer, e.g. price volume agreements,
udget capping, and discounts. 
ata sources and search strategy 
To identify studies that discussed challenges associated with
ED schemes for MDs, we conducted a search on the Web of Sci-
nce (WoS), Pubmed (National Library of Medicine), Embase, and
copus databases in September 2018. We supplemented this with
 search on the Google and Google Scholar databases in the same
onth and updated this search in January 2019. Furthermore, we
erformed a check on the reference lists of all full texts that we re-
iewed for eligibility for relevant studies that did not show up in
ur search results. The full electronic search strategy used for WoS
s available as Supplementary Material S2. This search strategy was
dapted for use on the other bibliographic and Google databases.
e did not register a systematic review protocol. er et al., Challenges with coverage with evidence development 
echnology, https://doi.org/10.1016/j.hlpt.2020.02.006 
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Fig. 1. PRISMA ﬂowchart of selection process 
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(tudy selection 
Two reviewers (VRD and CF) independently screened the titles
nd abstracts of all articles based on the predeﬁned eligibility
riteria. Subsequent to the screening of titles and abstracts, the
eviewers compared results and resolved disagreements by means
f dialogue. Articles that were potentially eligible for inclusion
nd those for which the dialogue could not settle disagreement
etween the reviewers were selected for full-text review. The
eviewers then independently reviewed the full texts, compared
esults, and again resolved disagreement by dialogue. Articles were
ncluded in the review if they met all eligibility criteria and both
eviewers agreed on their inclusion. 
ata abstraction 
The same two researchers applied a directed context analysis
pproach to extract data from the selected studies [17] , by using
 pre-deﬁned extraction template in Microsoft Oﬃce Excel. The
ollowing data were extracted: (1) author(s), (2) year, (3) country,
4) type of study, (5) type of health technology, (6) CED scheme for
D and the associated medical condition, (7) challenges associated
ith assessing the desirability of a CED scheme, (8) challenges
ssociated with choosing the research design for a CED scheme, (9)
hallenges associated with the implementation of a CED scheme,
10) challenges associated with the evaluation of a CED scheme,
nd (11) ‘other’ types of challenges associated with a CED scheme
or MDs, where items 7–10 relate to challenges associated with the
our good practice questions described in the Introduction section
nd item 11 relates to challenges that fall outside the scope of
hese questions [1] . The data were synthesised in a narrative
eview [18] . 
Although we excluded studies that discussed challenges with
ED schemes for pharmaceuticals from our main analysis, we also
xtracted the data from these studies in order to examine the sim-Please cite this article as: V. Reckers-Droog, C. Federici and W. Brouw
schemes for medical devices: A systematic review, Health Policy and Tlarities and differences between challenges associated with CED
chemes for MDs and pharmaceuticals. 
esults 
earch results 
The database search yielded a total of 4293 unique records;
258 records were yielded from WoS, Pubmed, Embase, and
copus, and 35 from Google and Google Scholar. The screening of
itles and abstracts resulted in the exclusion of 4196 records. The
ull-text review resulted in the exclusion of another 70 records.
he main reasons for exclusion were merely reporting on the
haracteristics, processes, and/or results of applied CED schemes
or MDs (n = 39) and discussion of challenges solely in the context
f pharmaceuticals (n = 22). The remaining 27 articles met all
ligibility criteria and were included in the review. Fig. 1 presents
he PRISMA ﬂowchart of the selection process. 
tudy characteristics 
Table 1 presents an overview of the general characteristics of
he included articles. Of the 27 studies included in the review,
 reported on challenges with CED schemes in the speciﬁc con-
ext of MDs and 21 on challenges with CED schemes in the con-
ext of different types of health technologies, including MDs. Most
tudies focused on one or more CED schemes applied in the USA
n = 10), followed by one or more European countries (n = 9), Aus-
ralia (n = 6), and Canada (n = 6). A total of 16 studies discussed
he challenges in the context of 55 existing CED schemes for MDs.
ost of these schemes were applied in Canada (Ontario) (n = 13),
ollowed by the USA (n = 11), UK (n = 9), Australia (n = 5), the
etherlands (n = 5), Germany (n = 5), France (n = 3), Belgium
n = 3), and Spain (n = 1). er et al., Challenges with coverage with evidence development 
echnology, https://doi.org/10.1016/j.hlpt.2020.02.006 
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Table 1 
General characteristics of the included articles 
# Author(s) [ref] Year Country of focus Type of Study 
Type of health 
technology a 
CED scheme(s) for MDs and associated medical 
condition b 
1 Tunis and Pearson [25] 2006 USA Theoretical All technologies ICDs for the prevention of sudden cardiac death in 
high-risk patients, Balloon angioplasty plus carotid 
stenting for patients with carotid artery disease, 
FDG-PET scan for diagnosis of dementia and 
various cancer types 
2 Hutton et al. [26] 2007 NS Theoretical All technologies NS 
3 Lindsay et al. [27] 2007 USA Case study MDs ICDs for the prevention of sudden cardiac death in 
high-risk patients, FDG-PET scan for various cancer 
types 
4 Carbonneil et al. [14] 2009 Australia, Belgium, 
Canada (Ontario), UK 
(England/Wales), 
Germany, Spain, USA 
Systematic review; 
Survey; Interviews 
All technologies Belgium: DBS, Endovascular treatment of 
abdonimal aneurysms, DES for diabetic patients, 
Cochlear implants; Canada (Ontario): PET scan, 
DES, cardiac CT angiography; France c : 
intensity-modulated radiation therapy, extracranial 
stereotactic radiotherapy; TAVI; Germany: 
screening for skin cancer; Spain: PET scan; USA: 
Cochlear implants, ICDs, PET scan 
5 Dhalla et al. [28] 2009 UK Survey All technologies HealOzone for treatment of tooth decay, 
Endovascular stent insertion for intracranial 
atherosclerotic disease, Soft-palate implant for 
simple snoring 
6 O’Malley et al. [6] 2009 Australia Case study MDs PillCam® Capsule Endoscopy for the evaluation of 
obscure gastrointestinal bleeding 
7 Goeree et al. [29] 2010 Canada (Ontario) Case study; Theoretical MDs and surgical 
procedures 
DES for patients with different medical conditions 
8 Menon et al. [30] 2010 Australia, Canada 
(British Columbia, 
Ontario, and Alberta), 
UK, USA 
Consensus statement All technologies NS 
9 Mohr and Tunis [24] 2010 USA Case studies All technologies Carotid artery stenting, Haemodialysis, FDG-PET for 
diagnosis of dementia and various cancer types, 
ICDs, Cochlear implant, Long-term oxygen therapy, 
Artiﬁcial heart, Sleep Apnoea, SCS for patients with 
chronic back and leg pain, Magnetic resonance 
guided focused ultrasound for the treatment of 
uterine ﬁbroids (pilot) 
10 Staﬁnski et al. [2] 2010 NS Review All technologies Australia: EVAR for treatment of abdominal aortic 
aneurysm, DBS for patients with Parkinson’s 
disease no longer responsive to pharmaceutical 
therapy, PET scan for various cancer types; Canada 
(Ontario): EVAR for treatment of abdominal aortic 
aneurysm, DES for patients with coronary artery 
disease, PET scan for various cancer types, 
diagnosis of solitary pulmonary nodule diagnosis, 
and patients with left ventricular dysfunction for 
whom revascularisation or cardiac transplantation 
was considered, EP for patients with refractory 
cutaneous T-cell lymphoma, MDCTA for diagnosis 
of coronary artery disease, ICDs for prevention of 
sudden cardiac death in patients with coronary 
heart disease, PVP for patients with benign 
prostatic hyperplasia, HBOT for treatment of 
chronic, non-healing, ulcers of the lower limb for 
patients with diabetes mellitus, NWPT (VAC 
system) for patients with chronic pressure wounds 
of the pelvic region; The Netherlands: SCS for 
patients with chronic non-oncological pain; USA; 
carotid artery angioplasty and stenting for the 
prevention of stroke in patients with carotid artery 
disease; PET scan for diagnosis of dementia and 
various cancer types, ICDs for prevention of sudden 
cardiac death in patients with life-threatening 
cardiac dysfunction, Long-term (home) oxygen 
treatment for patients with COPD, Artiﬁcial hearts 
for patients with severe biventricular end-stage 
heart disease who are not transplant candidates 
11 Trueman et al. [31] 2010 NS Summary of conference 
presentations; Review 
All technologies Canada (Ontario): DES 
12 Levin et al. [32] 2011 Canada (Ontario) Case studies All technologies DES, EVAR, 64-slide CT angiography, PET scan for 
various cancer types, EP, Insulin infusion pumps in 
the management of insulin-dependent type 2 
diabetes 
13 Mortimer et al. [33] 2011 Australia, UK, USA Theoretical All technologies Australia: DBS for patients in Parkinson’s disease, 
TUNA 
( continued on next page ) 
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Table 1 ( continued ) 
# Author(s) [ref] Year Country of focus Type of Study Type of health 
technology a 
CED scheme(s) for MDs and associated medical 
condition b 
14 Relyea-Chew [34] 2011 USA Case studies All technologies PET scan for diagnosis of 
dementia/neurodegenerative diseases and various 
cancer types 
15 Claxton et al. [22] 2012 NS; UK 
(England/Wales) 
Review; Case studies All technologies Canada: PET scan; USA: ICD, PET scan; UK 
(England/Wales) d : Prostheses for primary total hip 
replacement, Hearing aid technology, Metal on 
metal hip resurfacing for patients with hip disease, 
Photodynamic therapy for (age-related) macular 
degeneration, Carmustine implants for patients 
with glioma, SCS for patients with (chronic 
neuropathic or ischaemic) pain, Cochlear implants 
for patients with hearing impairment, 
Endovascular stent-grafts for patients with 
abdominal aortic aneurysm 
16 Walker et al. [35] 2012 NS Theoretical All technologies NS 
17 Bishop and Lexchin 
[36] 
2013 Australia, Canada, UK, 
USA 
Interviews All technologies NS 
18 Garrison et al. [1] 2013 NS Case studies; 
Theoretical; Taxonomy 
All technologies USA: PET scan for various cancer types, 
Percutaneous transluminal angioplasty and 
stenting for prevention of a second stroke, SCS for 
failed back surgery syndrome 
19 Brügger [12] 2014 Australia, Belgium, 
Canada (Ontario), 
France, Germany, The 
Netherlands, Sweden, 
Switzerland, USA 
Review; Case studies; 
Interviews 
All technologies Australia: HBOT for patients with non-diabetic 
ulcers; Canada (Ontario): DES, PET scan; Germany: 
PET scan for colorectal cancer, Balneo-phototherapy 
for patients with psoriasis, VAC therapy for chronic 
wounds, Brachytherapy for patients with prostate 
cancer; The Netherlands: Radiofrequency 
denervation for patients with chronic non-speciﬁc 
low back pain, Intra-arterial 
thrombolysis/thrombectomy in a stroke unit, Renal 
denervation for patients with treatment-resistant 
hypertension, Transluminal endoscopic step-up 
approach in patients with infected pancreatic 
necrosis; USA: PET scan, Artiﬁcial hearts, TAVI, 
Cochlear implant, FDG-PET scan for diagnosis of 
dementia 
20 Foster et al. [37] 2014 USA Commentary MDs FDG-PET scan for patients with dementia 
21 Launois et al. [38] 2014 NS Theoretical; Taxonomy All technologies NS 
22 Martelli and van den 
Brink [39] 
2014 France Theoretical MDs NS 
23 Drummond [13] 2015 NS Theoretical All technologies NS 
24 Garrison et al. [40] 2015 USA Review; Survey; 
Interviews 
All technologies NS 
25 Kanavos et al. [23] 2017 NS Theoretical; Taxonomy All technologies NS 
26 Rothery et al. [19] 2017 NS Theoretical MDs NS 
27 van de Wetering et al. 
[15] 
2017 The Netherlands DCE All technologies NS 
COPD, chronic obstructive pulmonary disease; CT, computerised tomography; DBS, deep brain stimulation; DCE, discrete choice experiment; DES, drug-eluding stents; EECP, 
enhanced external counterpulsation; EP, extracorporeal photopheresis; EU, Europe; EVAR, endovascular aneurysm repair; FDG-PET, ﬂuorodeoxyglucose - positron emission 
tomography; HBOT, hyperbaric oxygen therapy; HTA, health technology assessment; ICD, implantable cardioverter-deﬁbrillator; MD, medical device; MDCTA, multidetector 
computed tomographic angiography; NICE, National Institute for Health and Care Excellence; NPWT, negative pressure wound therapy; NS, Not Speciﬁed; PET, positron 
emission tomography; PVP, photo selective vaporisation of the prostate; SCS, spinal cord stimulation; TAVI, transcatheter aortic valve implantation; TUNA, transurethral 
needle ablation; UK, United Kingdom; USA, United States of America; VAC, vacuum-assisted closure system 
a All technologies are including MDs. 
b The associated medical condition is presented if speciﬁed by the authors. 
c Recommended by national HTA agency, but scheme not initiated. 
d Recommended by NICE. 
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We extracted information on 17 challenges from the included
tudies that were associated with assessing the desirability, choos-
ng the research design, implementation, evaluation, and ‘other’
ypes of challenges with CED schemes for MDs. In particular, these
7 challenges concern: (1) deciding on whether a CED scheme is
esirable, (2) understanding the relevant uncertainties and risks,
3) lengthy and complex negotiations, (4) deﬁning the decision
roblem, (5) data requirements, (6) identifying meaningful out-
omes, (7) deﬁning an adequate duration for a scheme, (8) market
ntry of new technologies during a scheme, (9) obtaining fund-
ng, (10) obtaining informed consent, (11) quality of the data,Please cite this article as: V. Reckers-Droog, C. Federici and W. Brouw
schemes for medical devices: A systematic review, Health Policy and T12) deciding on when a scheme is considered successful, (13)
ithdrawing a technology, (14) lack of transparency, (15) lack of
overnance, (16) stakeholder involvement, and (17) ethical issues.
able 2 presents a description of each of these challenges. A full
verview of the extracted challenges, including those extracted
rom studies discussing the challenges solely in the context of CED
chemes for pharmaceuticals, is available as Supplementary Mate-
ial S3. 
These challenges apply to some extent to all CED schemes for
ifferent types of technologies; however, ﬁve relate directly to the
haracteristics of MDs, and hence are speciﬁc to MDs. Most of
hese speciﬁc challenges were discussed by Rothery et al. (2017)
nd relate to deciding on whether a CED scheme is required,er et al., Challenges with coverage with evidence development 
echnology, https://doi.org/10.1016/j.hlpt.2020.02.006 
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Table 2 
Challenges associated with CED schemes for MDs a 
# Challenge Description 
Desirability 1 Deciding on whether 
a CED scheme is 
required 
Whether CED schemes are recommended depends on both the characteristics of the technology (whether it is 
expected to have a positive net beneﬁt, whether evidence can be generated following reimbursement, and whether 
there would be a cost in reversing the decision at a later data) and the range of authority of the purchaser (whether 
they can delay a decision or review it at later date, whether they can negotiate price, and whether they can ensure 
that research is actually conducted) [35] ; 
Generally, there is a lack of criteria and formal guidelines that can help decide whether a CED scheme can help 
reduce uncertainty and should be initiated [12 , 28 , 39] ; 
The question of whether or not further research is worthwhile requires some assessment of how uncertain a 
decision based on expected cost-effectiveness might be, what the consequences are likely to be if an incorrect 
decision is made, and what a technology that has been subjected to a CED scheme is displacing [22] ; 
There is a close link between the value of a MD, the value of further research to reduce uncertainty and the price of 
the MD. These links can offer incentives for manufacturers to price accordingly and decide whether there is 
suﬃcient value from further evaluative research. The value of additional research can be informed through VOI 
analysis [19]. However, VOI analysis may be diﬃcult to apply in speciﬁc cases and a formal guideline may help 
decide whether research in a particular area is practical and likely to reduce uncertainty [28] . This should be 
enhanced, in particular by clearly stating the selection criteria for MDs that may beneﬁt from such approaches [39] ; 
There is a concern that CED schemes could stiﬂe or slow innovation by creating a disincentive to develop new 
products for conditions for which the evidence base is not well developed or by raising the evidentiary standards 
[24,41] ; 
CED schemes may have the unintended effect of lowering industry investment in evidence development and 
shifting research costs to public fund holders [33] ; 
There is a concern that manufacturers use CED schemes as a mechanism to secure beneﬁcial formulary placement, 
gain market share, and increase patient compliance. Manufacturers may be reluctant to take on the risk of a CED 
scheme when they cannot predict how their product will be used in the real-world population [40] . 
2 Understanding the 
relevant uncertainties 
and risks 
There are challenges in assessing risks upfront due to uncertainties in the real-world performance of a technology 
and further research is unlikely to be able to resolve all uncertainty [31,33] ; 
Some uncertainties cannot be reduced by further research and may resolve by other changes occurring over time. 
For example, the effective price of the technology and/or its comparators may change. The price plays a key role in 
determining the value of the technology, but it also affects the level of uncertainty by changing the likelihood of 
making an incorrect decision and the value of further research [19] . Other uncertainties that cannot easily be 
resolved by further research may concern previously unrecognised adverse effects that emerge in the long term and 
changes in market conditions that might cause the price of the technology to drop in the future [13] ; 
One of the complexities associated with the evaluation of MDs is the fact that any decision about the adoption of 
the MD will interact with the ability to gather more evidence and may affect future commercial developments of 
the technology [19] ; 
There is a group of concerns relating to the introduction of additional uncertainty for manufacturers in terms of 
expected returns, which may have the opposite effect of dis-incentivising additional data collection, the advantage 
competitors may take of data collected by the manufacturer, and related to this is the problem of free-riding [23] . 
3 Lengthy and complex 
negotiations 
Deﬁning the study design is often lengthy and complex, and it may be diﬃcult to reach contractual agreement 
[32,40] ; 
Deciding on the point in the product life cycle at which a technology should be assessed is a contentious issue and 
various stakeholders may have different views on the technologies that require further study, the questions that 
need to be answered, and the necessary methods for answering those questions. It requires the creation of working 
groups made up of key stakeholders and opinion leaders who are involved in designing the study questions and 
methods from the beginning of the process [25,26] ; 
There is protocol development, sample size and site determination, case report form development, contracts with 
sites and investigators and dealing with multiple ethics boards submissions, therefore, study initiation is often 
subject to contractual and legal delays [32] . 
Research design 4 Deﬁning the decision 
problem 
The decision problem is rarely stated explicitly and this creates the risk that the study design does not address the 
decision problem or is not designed to feasibly address that problem [30] ; 
The research design that is most appropriate depends on the nature and type of the uncertainty that the CED 
scheme is trying to address, e.g. uncertainty about whether the medical product or service will be used in the right 
patients or uncertainty at launch about clinical or economic outcomes [42] . 
5 Data requirements A formal guideline for CED schemes should be accompanied by a clear statement regarding what study design and 
data are required to reduce uncertainty [45] . Requirements are often not speciﬁed and laws can be unclear at this 
point [39] ; 
The study design that is required to answer questions of evidence development is often not clearly deﬁned, 
especially concerning the need for RCTs or observational/not experimental designs [31] ; 
For the establishment of registries, there are generally no guidelines available [6] ; 
The design of a study should not take place when the decision is made over who should pay for the study as this 
may impose restrictions [22] . 
6 Identifying 
meaningful outcomes 
Outcome measures should be clear, measurable, objective, realistically achievable (in relation to the duration of the 
scheme), and relevant [1] ; 
It is important to be certain that the outcomes of interest are largely inﬂuenced by the technology concerned [13] ; 
Manufacturers and payers may shy away from agreements in disease areas where there are many different 
treatment paradigms or the relevant outcome is an intermediary outcome, because it can be challenging to 
attribute the outcome to the product in question. There is also a risk for manufacturers with being responsible for 
outcomes when they cannot control the way a technology is used [40] ; 
Uncertainty about the eﬃcacy of a MD and the learning or training required to achieve the desired eﬃcacy can 
result in adverse consequences on patient outcomes and lead to an ineffective use of healthcare resources [19] ; 
When questionnaires for data collection are designed by physicians, they may not be ideal for use in an economic 
analysis [6] ; 
In some cases, the ‘right’ outcomes may not identiﬁed until the scheme is implemented, resulting in failure to 
capture the data needed to reduce the decision-making uncertainty [2] . 
( continued on next page ) 
Please cite this article as: V. Reckers-Droog, C. Federici and W. Brouwer et al., Challenges with coverage with evidence development 
schemes for medical devices: A systematic review, Health Policy and Technology, https://doi.org/10.1016/j.hlpt.2020.02.006 
V. Reckers-Droog, C. Federici and W. Brouwer et al. / Health Policy and Technology xxx (xxxx) xxx 7 
ARTICLE IN PRESS 
JID: HLPT [m5G; February 29, 2020;8:31 ] 
Table 2 ( continued ) 
# Challenge Description 
7 Deﬁning an adequate 
duration for a scheme 
Designing the necessary clinical research, getting funding, and implementing a scheme in a time frame that is 
consistent with the needs of clinicians, patients, and other decision makers is challenging [25] ; 
With a typical three- to ﬁve-year political cycle, there is often a tension between research and political needs [29] ; 
Short-term schemes are not desirable given the considerable investment in evidence development, while long-term 
deals are also not desirable given the costs and risks involved [40] ; 
The unique characteristics associated with MDs, such as rapid incremental innovation, learning effects, and upfront 
irrecoverable costs all present a challenge for the timing of reimbursement decisions and the value of waiting until 
additional evidence is conducted to support the technology [19] ; 
In view of the pace of technological changes in healthcare, a CED scheme of more than three years may be of 
limited relevance for MDs [26,43] . This is because the kinds of policy questions that such studies inform have the 
habit of changing, for example, as other technologies become available for the same patient group [13] . 
8 Market entry of new 
technologies 
The information generated by research will not be valuable indeﬁnitely as new and more effective interventions 
may become available and make the information no longer relevant for future clinical practice [19] ; 
Market access of incremental MD innovations and new technologies may make existing ones obsolete or change 
their cost-effectiveness [26,33] ; 
Rapid approval of new entrants may result in a disincentive for manufacturers to invest in further research that 
would reduce uncertainties about MDs eﬃcacy [19] ; 
MDs that enter the market during a CED scheme may not be included in the scheme, and hence reports may be 
based on evidence from only one MD [6] . 
Implementation 9 Obtaining funding The costs associated with CED schemes can be substantial and a barrier to establishing a viable and cost-effective 
scheme [1,28,29,36,40,44] ; 
CED schemes are perceived to have high transaction costs and be diﬃcult to execute, particularly given the 
fragmented payer system with patient movement across plans, as well as the current lack of data infrastructure that 
limits feasibility and, to some extent, interest in measuring long-term outcomes [40] ; 
It may take years before funding is ensured and then there may still not be suﬃcient funding to generate the 
evidence needed to reduce uncertainties and meet the HTA agency and decision makers requirements [14,22,25] ; 
Lack of experience with CED schemes, staff turnover, billing requirement complexity, and inconsistency of 
nonresearch and research requirements may add up to signiﬁcantly more time and effort than anticipated, at times 
for studies with no funding for administration [37] ; 
Some have suggested establishing public-private partnerships between payers and manufacturers, while others have 
stressed the importance of locating publicly funded research organizations who may be perceived as neutral and, 
therefore, better able to provide control over research design and data, and manage vested interests [2,31] . 
10 Obtaining informed 
consent 
Identifying and counselling potential participants and obtaining informed consent requires considerable effort and 
patients may decline to participate or may prematurely withdraw. The need for frequent reconsent, e.g. when 
regulations change mid study, should be taken into account [37] ; 
If patients or physicians withhold consent, the patients’ data will not be used for research, but it will still be stored, 
e.g. in a registry, and may still be reimbursed under a CED scheme [27] . 
Evaluation 11 Quality of the data It may be diﬃcult to obtain consensus amongst stakeholders about what is considered an acceptable quality of 
evidence [22]; 
After coverage or reimbursement is obtained for a technology, there may be a lack of incentive, e.g. for 
manufacturers, to collect the data [25] ; 
There is the risk that research may not happen, does not answer the initial questions, does not feed back into 
decision making and the technology is funded anyway, or does not deliver the evidence while the funding cannot 
be stopped [12] ; 
Evidence generated may not meet the quality criteria or be suﬃcient for making coverage decisions, e.g. when 
relying on observational data alone [2,12,14] ; 
The accuracy, reliability, and completeness of the data, e.g. when submitted to a registry, often depends on 
physicians and they may not always have the necessary time to complete the forms accurately [5,17,28] ; 
Physicians are not (always) paid for data collection and reporting, which may affect the quality of the data, and 
there may substantial missing data, e.g. due to loss to follow-up in registries, which may lead to bias [6] ; 
There is an additional burden to monitoring a CED scheme and of collecting and analysing the data collected as part 
of a CED scheme. This may affect the quality of the data [26] ; 
For the success of a scheme, it is imperative that payers and manufacturers trust the data and clear agreements on 
data validation and analysis are important to create this trust [40] . 
12 Deciding on when a 
CED is considered 
successful 
There still is little evidence to support the claimed beneﬁts of CED schemes and the extent to which some of the 
challenges involved in CED scheme implementation impact on the ﬁnal outcome [23] ; 
It is not clear if CED schemes succeed in limiting reimbursement to speciﬁc patient subgroups and payers are 
sceptical that CED schemes will reduce costs in the long run [23,24] ; 
As it may not be possible to assess the VOI generated by a CED scheme directly post hoc, there is a need to rely on 
process indicators for assessing a scheme’s success. Such process indicators should relate to the research questions 
relating to the design, implementation and evaluation of the scheme and include the questions, i.e. are the intended 
outcome measures collected, was uncertainty in associated parameter estimation reduced for the outcomes that 
were the focus of the scheme, did the scheme run to budget and time, was the integrity of the design/estimation 
maintained, did the governance arrangements work well, and did the success to underpin a decision with further 
evidence prove successful [1] ; 
Whether the CED scheme has achieved its objectives and can be considered good value from a health system 
perspective is linked to the desirability of the scheme and can be addressed from multiple perspectives: 
manufacturer, patient, payer, provider, and society. A comprehensive evaluation will therefore need to consider 
multiple perspectives [1] ; 
The success of CED schemes when manufacturers are asked to conduct the research will depend on whether the 
authorities are able to establish contractual arrangements as part of a CED scheme, that is, arrangements that can 
be monitored and enforced with credible penalties to ensure that agreed research is conducted and in the way 
intended [22] . 
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Table 2 ( continued ) 
# Challenge Description 
13 Withdrawing a 
technology 
Once a technology is used in practice–even if formally temporary–ending reimbursement may be less feasible than 
initially not reimbursing it, especially when the technology proves to be effective, but not cost-effective [1,15,26] ; 
Decisions to withdraw may cause heated discussions with doctors, patients, and politicians and be followed by a 
public debate in the media [12]; 
Patients may also be more motivated to exert political pressure to secure or maintain coverage of last-line 
treatment for life-threatening illnesses than for preventative or ‘me-too’ interventions. Inertia in clinical practice 
may be a barrier to delisting, particularly for interventions with a long-standing place in both formularies and 
clinical practice. Payers may adopt a passive role and rely upon clinicians to modify their prescribing practice to 
replace inferior interventions with more effective or better-tolerated alternatives as and when they become 
available. Evidence development may be delayed if the default position is to extend funding until the data become 
available [33] . 
Other 14 Lack of transparency There is a general lack of information on CED schemes in the public domain that is attributed to ‘commercial 
conﬁdentiality’. Consequently, payers who consider CED schemes as a potential policy option have little information 
upon which to base a decision [2] ; 
There is little information available on the agreements implemented, their objectives, and evaluation of their 
impact. This prevents cross-country learning and limits the ability of patients to engage with CED processes [23] ; 
Disclosure of the results of previous schemes related to a technology of interest may reduce duplication of effort s. 
Mechanisms for increasing transparency around key components, e.g. objectives, conﬂicts of interest, data collection 
management, and oversight, of the scheme that respect commercial interests are required to build on previous good 
research practices for speciﬁc types of studies [1,2] . 
15 Lack of governance Lack of project management and coordination can be an obstacle for CED schemes and can make it diﬃcult to 
ensure an update of the recommendation following the production of new evidence [12,14,22] ; 
The independence of a scheme from any party with a vested interest in its outcomes should be ensured [30] ; 
Stakeholders may take contradictory positions (also amongst themselves) around where the leadership should rest 
and which stakeholders should be involved in a CED scheme [36]; 
Supervision of the research may create a conﬂict of interest for a HTA body as they need to keep the image of being 
a helper for a better quality healthcare system [12] . 
16 Stakeholder 
involvement 
The various stakeholders can affect political decisions around the initiation of a CED scheme. For example, 
manufacturers may pressure the initiation of a scheme and conﬂicts of interest may arise when manufacturers play 
a role in the funding, data collection, and evaluation of a scheme [36] ; 
Patients, generally, have limited opportunities to engage in the development of a scheme and not all patient groups 
are aware of what CED schemes entail [23] ; 
Patient advocacy groups may be unwilling to accept this policy especially if the assessed treatment is considered to 
be safe and eﬃcacious [22] . They may distrust the motives of payers in their effort s to support evidence 
development through coverage, and may assume that the primary objective is cost containment, rather than a 
genuine effort to support early access to innovations and clinical research [24] ; 
There may be signiﬁcant opposition from the clinical community and compliance with data collection by physicians 
may be weak, e.g. because of lack of staff [11,31] ; 
There is the risk that CED schemes are perceived as a tool for monitoring or controlling physicians, particularly in 
the context of registers on interventional procedures with or without the use of MDs [40] ; 
Compliance with data collection by physicians may be weak and the monitoring of the study poor because of lack 
of clinical staff [12] ; 
The translation of evidence into policy is riddled with political and economic considerations, both the overt political 
process involved in CED and the role of the pharmaceutical industry. The most explicit evidence of relations of 
power comes from the hierarchy of roles in the decision-making process. Political inﬂuences play a role in 
determining where the money for CED will come from and where the ultimate decision-making comes from [36] . 
17 Ethical issues CED schemes may be beneﬁcial for future patients, but they can impose signiﬁcant opportunity costs on current 
patients. Some individuals in the present population may beneﬁt from the research condition because they will also 
be members of the future population. However, this will not be true for all and so the issue of balancing the 
interests of some individuals in the present population against some individuals in the future population remains 
[22] ; 
Various stakeholders, e.g. policy makers and patient groups, have questioned whether it is ethical to restrict access 
to technologies to patients participating in registries and clinical trials, and to withhold a potentially beneﬁcial 
innovation from a subset of patients who cannot, or will not, participate while providing it to another 
[12,22,24,25,31,34] . It is also questioned whether study participation concerns coercion and whether patients’ 
informed consent is valid in this context [24,25,34] ; 
Patient advocacy groups may be unwilling to accept a CED scheme, especially if the treatment has demonstrated 
safety and eﬃcacy [31] ; 
Furthermore, CED schemes may result in inequities as participants in the treatment arm may receive better 
treatment than those in the other arm and those not participating, and treatments may not be available in all 
geographical areas [22,34] . 
AWR, approval with research; CE, Conformité Européenne; CED, coverage with evidence development; FDA, Food and Drug Administration; GRP, good research practice; NICE, 
National Institute for Health and Care Excellence; OIR, only in research; RCT, randomised controlled trial; USA, United States of America; VOI, value of information. 
a For reasons of clarity, we used the term CED scheme in this table, where the author(s) at times used the terms performance-based risk sharing agreement or access 
with evidence development scheme. The original terms used by the author(s) can be found in Supplementary Material S3. The classiﬁcation of challenges into ‘Desirability’, 
‘Research design’, ‘Implementation’, and ‘Evaluation’ of CED schemes relate to the four good practices questions that were formulated by ISPOR’s ‘Good Practices for PBRSA 
Task Force’ [1] . ‘Other’ relates to challenges that fall outside the scope of these questions. 
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t  ﬃcacy. This may lead to a situation in which research costs shift
o public fund holders. Furthermore, the changes over time in
rices of MDs and due to gradual innovations can complicate
eﬁning an adequate duration for a scheme and this, in turn, may
mpact the identiﬁcation of and data collection on meaningful out-
omes. The identiﬁcation of meaningful outcomes may also be par-
icularly challenging for MDs as the outcomes of interest are typ-
cally not only inﬂuenced by the MD, but also by the subsequent
reatment, e.g. as is the case for diagnostic MDs such as positron
mission tomography (PET) scans. Furthermore, MDs’ effectiveness
s not only inﬂuenced by characteristics of the MD itself but may
o a large extent be inﬂuenced by the learning or training of physi-
ians that is required to achieve the optimal effect. The associated
earning curve of physicians may result in a more modest impact
n patient outcomes or higher costs during the early use of MDs,
esulting in a lower cost-effectiveness of MDs when assessed in the
hort run or early in the development phase. 
A qualitative assessment of the similarities and differences be-
ween challenges associated with CED schemes for MDs and other
ypes of technologies, e.g. pharmaceuticals, did not reveal any chal-
enges with CED schemes for other types of technologies that do
ot also apply to MDs. However, we identiﬁed three challenges
hat were discussed in the context of CED schemes for pharmaceu-
icals that were not found in the included studies, yet are also con-
idered to be applicable to MDs. The ﬁrst challenge concerns the
nformation asymmetry between payers and manufacturers about
he potential real-world performance of a technology and the im-
act this may have on CED-scheme agreements [20] . The second
hallenge concerns the ex-ante deﬁnition of a ﬁnal decision rule
ased on the gathered information and ‘exit strategy’. It needs
o be deﬁned when the (cost-) effectiveness and/or safety of a
echnology is deemed to be below expectations or some relevant
hreshold, leading to its withdrawal or a premature termination of
he CED scheme [11] . Ideally, this would also entail a withdrawal
mplementation plan. The third challenge concerns the economies
f scale in the management of CED schemes and the diﬃculties
mall countries may have in applying CED schemes because of the
ssociated costs and monitoring mechanisms [20] . 
iscussion 
The objective of this study was to identify and describe the
hallenges that payers and manufacturers might face when as-
essing the desirability of, choosing the research design for, im-
lementing, and evaluating CED schemes for MDs. We identiﬁed
0 distinct challenges that are associated with CED schemes for
Ds. Most of these challenges are not speciﬁc for MDs; how-
ver, ﬁve are, as they relate directly to the characteristics of MDs.
hese challenges concern deciding on whether a CED scheme is
equired, understanding the relevant uncertainties and risks, iden-
ifying meaningful outcomes, deﬁning an adequate duration for a
cheme, and market entry of new technologies during the exis-
ence of a scheme. The majority of studies discussed challenges
ith CED schemes in the context of applied CED schemes for MDs.
enerally, studies discussed challenges with CED schemes for all
ypes of technologies and only few speciﬁcally discussed them for
Ds. Most of the challenges that relate to the characteristics of
Ds were discussed by Rothery et al. (2017). 
These results suggest that the challenges associated with
ED schemes for MDs and the relationship between these chal-
enges and the characteristics of MDs are infrequently researched.
lthough the many similarities between challenges with CED
chemes for MDs and other types of technologies, such as phar-
aceuticals, may have reduced the need for research in this area,
hese results can still be considered remarkable given the consider-
ble decision uncertainty associated with coverage and reimburse-Please cite this article as: V. Reckers-Droog, C. Federici and W. Brouw
schemes for medical devices: A systematic review, Health Policy and Tent of MDs and the direct relevance of CED schemes in this con-
ext. Our ﬁnding that challenges with CED schemes for MDs are
nfrequently researched is further illustrated by the fact that this,
o our knowledge, is the ﬁrst systematic review of the literature
hat focuses speciﬁcally on this topic. Although we consider this
 strength, some limitations also deserve attention. Firstly, CED
chemes go under many different names and some schemes that
re applied for MDs may have a conﬁdential nature [12 , 14 , 21] .
onsequently, we cannot rule out the possibility that there are
hallenges associated with CED schemes for MDs that we have not
dentiﬁed and described in our review. We also cannot rule out the
ossibility that there are CED schemes for MDs that are not iden-
iﬁed and mentioned in our review ( Table 1 ), as we excluded arti-
les that merely reported on the characteristics, processes, and/or
esults of applied CED schemes. However, this limitation does not
ffect our main ﬁndings. Secondly, we synthesised our results in
 qualitative rather than a quantitative review. Hence, our review
oes not provide information about the extent to which the char-
cteristics of MDs impact on the challenges associated with CED
chemes, nor about the frequency and intensity with which the
hallenges occur in practice. Finally, some of the studies included
n our review applied a combination of methods to gain insight
nto challenges associated with CED schemes that are not technol-
gy speciﬁc. For example, Carbonneil et al. (2009), Claxton et al.
2012), and Brügger (2014) have supplemented their review of the
iterature with one or more case studies, a survey, and/or inter-
iews with experts. Future research may be aimed at gaining addi-
ional insight into the challenges speciﬁcally associated with CED
chemes for MDs, for example, by conducting interviews with pay-
rs who are experienced in applying these schemes. 
Future research may also be aimed at validating and deepen-
ng the understanding of the identiﬁed challenges and examining
ossible differences in (the intensity of) challenges associated with
ED schemes for different types of MDs, i.e. implantable, diag-
ostic, and therapeutic devices. Interviews may, for example, also
rovide insight into whether high upfront investment costs pose
ore of a challenge than rapid incremental innovation for CED
chemes for diagnostic devices such as PET scans. Furthermore, we
ould like to note that the challenges were mainly described from
he perspective of payers and manufacturers of MDs, even though
ome of the identiﬁed challenges with CED schemes directly re-
ate to the role of other stakeholders, such as patients and physi-
ians. Future research may be aimed at obtaining insight into pos-
ible additional challenges that are associated with CED schemes
or MDs, e.g., from the perspective of other stakeholders, that are
ot yet identiﬁed and discussed in this review, yet may also be
onsidered relevant for those who (intend to) apply CED schemes
or MDs. 
To improve a CED scheme’s chance of success, it is considered
mportant that payers and manufacturers of MDs have insight into
nd address the challenges described in this review. However, the
hallenges associated with evaluating CED schemes for MDs make
t clear that there is little evidence to support the claimed ben-
ﬁts of CED schemes [23] . Indeed, studies infrequently report on
he outcomes of CED schemes and little is known about their im-
act on patients’ access to technologies and the reduction of costs
n the long run [20 , 23 , 24] . Public sharing of information about
he outcomes of applied schemes may reduce the overlap in CED
chemes for MDs between countries as, for example, observed for
he USA, Australia, Canada (Ontario), Germany, and Spain. These
ountries have all applied a CED scheme for PET scans for diagnosis
f dementia and/or various cancer types. Public sharing of informa-
ion about the outcome of applied schemes and the way in which
arious stakeholders have addressed the challenges they faced
hen applying (or participating in) CED schemes for MDs may fur-
her improve a CED scheme’s chance of success. For example, byer et al., Challenges with coverage with evidence development 
echnology, https://doi.org/10.1016/j.hlpt.2020.02.006 
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 increasing cross-country learning, reducing the costs of individual
schemes, improving the design of future schemes, and increasing
trust amongst payers that CED schemes are a valuable option. 
Conclusions 
The results of this study indicate that there are at least 20
challenges that payers and manufacturers might face when apply-
ing CED schemes for MDs. Some of these challenges are speciﬁc
to MDs, given their distinct characteristics, but many are relevant
more generally. The MD-speciﬁc challenges concern deciding on
whether a CED scheme is required, understanding the relevant
uncertainties and risks, identifying meaningful outcomes, deﬁning
an adequate duration for a scheme, and market entry of new tech-
nologies. It is considered important that payers and manufacturers
of MDs are aware of, and where possible proactively address, these
challenges when considering the use of a CED scheme, also to
improve its chances of success and ﬁnal reimbursement decisions.
Public sharing of information about the outcomes of applied
schemes and the way in which various stakeholders have ad-
dressed the challenges they faced when applying (or participating
in) CED schemes for MDs may further improve their future use and
contribute to better decision making in health care. 
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